Nervous Disorder TRIZ Cases

Controlled release excipients provide pH-independent drug delivery to maintain stable plasma levels and reduce peak-related drowsiness.

Selective alpha-7 nicotinic acetylcholine receptor agonists treat narcolepsy symptoms while minimizing side effects and drug abuse potential.

Anti-TMEM106B antibodies bind the target protein to reduce levels or inhibit ligand interactions for therapeutic use.

An enzyme-based preparation converts alcohol to acetate, eliminating toxic acetaldehyde buildup without blocking endorphin release.

Oral Blautia hydrogenotrophica reduces mechanical allodynia, addressing uncharacterized fibromyalgia pathophysiology.

Targeting Siglec-3 with a monoclonal antibody enhances phagocytic removal of neurotoxic peptides to reverse neurodegeneration.

Strategic mismatches at nucleotide positions 1, 7, and 14 eliminate sense strand inhibition of antisense activity, restoring gene silencing efficiency.

Anti-MS4A4A antibodies bind specific epitopes to modulate protein activity, treating neurodegenerative diseases.

Sodium and potassium cations restore electrolyte balance disrupted by alcohol-induced diuresis, reducing headache and fatigue.

Fusion protein merges CD86 blockade with IL-10 signaling to extend therapeutic duration and reduce administration frequency.

Using EGF and FGF activators maintains neural stem cell homogeneity during expansion.

Exogenous miRNA enhances nuclear reprogramming efficiency while reducing tumorigenesis risks associated with viral vectors.

Selective p38α MAPK inhibitor neflamapimod reverses synaptic dysfunction and endosomal defects in dementia with Lewy bodies.

Permanent channels in absorbent structures enhance liquid transport while preventing stiffness caused by superabsorbent polymer loading.

Opiorphin inhibits NEP and APN enzymes to potentiate endogenous enkephalins, avoiding dependency and tolerance from traditional psychostimulants.

Monoamine oxidase inhibitors reduce convulsive seizure frequency in CDKL5 deficiency disorder.

Fully human monoclonal antibodies target the NKG2D receptor to provide a safer therapeutic option for treating autoimmune and inflammatory diseases.

Anti-CD300LB antibodies activate microglial signaling to promote apoptotic cell clearance in neurodegenerative disorders.

Volatile mobility-enhancing agents reduce particle glass transition temperature to accelerate solvent diffusion during secondary drying.

Segmenting full-length proteins into resectin fragments reveals novel extracellular signaling activities, enabling new biotherapeutic targets.

Liposoluble polyphenol derivative potentiates neprilysin activity to degrade amyloid-beta, addressing disease progression without conventional side effects.

Phosphate buffers stabilize 190 mg/mL natalizumab, resolving aggregation risks at high concentrations.

A controlled drying process establishes precise dosage sizes in ingestible films by preventing active ingredient aggregation.

Mutated AAV capsids deliver miRNA to deep cerebellar nuclei, reducing Atxn1 mRNA levels while minimizing off-target toxicity.

Conjoint Compound A administration with antiseizure medications targets refractory epilepsy by enhancing Kv7 channel opening.

Selective subunit binding activates heteromeric KCNQ channels, reducing side effects from non-specific openers like retigabine.

Antibodies targeting catalytic zinc ions overcome small molecule drug resistance and low solubility.

Enzymatic hydrolysis of silk fibroin using bromelain and protease mixtures overcomes low yield and poor absorption rates inherent in intact protein processing.

Specific promoters link reprogramming factors to glial progenitors, eliminating mixed populations and refractory dyskinesias.

A red ginseng extract preparation method using far-infrared irradiation and mechanical pressure to enhance ginsenoside concentration.

Antibodies activate TREM2 without blocking natural ligands, preventing loss-of-function disease risks.

Tricyclic 3,7-diazabicyclo[3.3.1]nonane derivatives resolve short-term effect limitations by providing stable allosteric modulation with reduced side effects.

Mucoadhesive cannabinoid films resolve alcohol irritation by using nanoemulsions to boost bioavailability.

Administering a REST inhibitor restores glial potassium uptake and corrects neuropsychiatric pathology linked to impaired ion transport.

A kit of odorant mixtures with varying proportions measures olfactory discrimination capacity to assess psychiatric conditions.

Novel selective FKBP51 ligand derivatives induce conformational changes in the target protein to enhance neuritogenesis.

Wearable and non-wearable sensors measure physiological activity to dynamically update personalized hypnotherapy session scripts.

Methylated tau peptides generate antibodies targeting pathological protein modifications, enabling non-invasive detection of sporadic Alzheimer's disease.

Extracted RGM binding domains enable antibody production to neutralize inhibitory activity and stimulate nerve fiber growth.

AFMT analogs block gut microbial tyrosine decarboxylase, preventing peripheral L-dopa metabolism and stabilizing brain drug levels.

Ganoderma lucidum extracts inhibit microglial activation to reduce toxic factors and protect dopaminergic neurons in Parkinson's disease.

Modifying AAV capsid sequences overcomes low transduction efficacy for oligodendrocytes, enabling targeted gene expression.

Cyclic peptides mimic amyloid-beta hairpin structures to induce specific antibody production.

Electron beam irradiation crosslinks polysaccharides without organic solvents, eliminating toxicity and enabling safe drug delivery.

Auranofin crosses the blood-brain barrier to inhibit PKC, lowering BACE1 levels and reducing Aβ production for neurodegenerative treatment.

Fatty acid conjugation extends the half-life of apelin peptides, providing sustained APJ receptor agonism and reducing administration frequency.

Oral neuropeptide Y overcomes gastrointestinal degradation barriers to reduce CNS inflammation in autoimmune encephalomyelitis models.